DailyIQ
Last updatedUpdating…

SYK·Stryker Corporation

$280.13
-2.42 (-0.86%)
High
$285.66
Open
$285.66
Market Cap
108.48B
52W High
$392.55
Low
$278.57
P. Close
$280.13
P/E
29.09
52W Low
$267.00
Fwd P/E
16.93
DailyIQ Est.
$379.24
Inst. Ownership
35.2%
Short Interest
1.50%
Days to Cover
2.0
Div. Yield
1.25%
Next Ex-Div
~Dec 31
Div. Growth
15+ yrs
Technical Score (1D)
16
BEARISH
News Sentiment
64
BULLISH
On Oct 12, Stryker reported a rebound in its second‑quarter operating performance after a cybersecurity disruption earlier in the year, restoring momentum to its business. The company said revenue growth was driven by new product launches and expanded market reach. Management highlighted continued investment in innovation and a focus on high‑margin segments, positioning the firm for sustained upside. The report underscored that the recovery followed the earlier setback and that the company is actively expanding its portfolio.
LOW TARGET
$298 +6.4%
2 analysts
MEAN TARGET
$363 +29.4%
12 analysts
HIGH TARGET
$465 +66.0%
22 analysts
PRICE RANGE
$298.00 - $465.00
SB / B / H / S / SS
12/15/7/1/1
DAILYIQ EST.
$379.24 (+35.4%)
Sector
Healthcare
Industry
Medical Devices
Exchange
NYQ
Country
United States
Symbol
SYK
Description
Stryker Corporation is a medical technology firm focused on providing innovative solutions for healthcare professionals. The company operates through two primary segments: MedSurg and Neurotechnology, and Orthopaedics. Its MedSurg and Neurotechnology division offers a diverse portfolio of surgical equipment, neurotechnology devices, and related products used in a variety of procedures, including minimally invasive interventions. The Orthopaedics segment specializes in implants for joint replacements and trauma surgeries, as well as spinal fixation systems. Stryker distributes its products globally to hospitals and healthcare providers in approximately 75 countries through a combination of direct sales and third-party distribution channels.
Bought (1Y)
131 shares
$27K
Sold (1Y)
666,704 shares
$216.7M
Wells Preston WendellVP, Chief Financial Officer
J109 shares2026-09-24
Wells Preston WendellVP, Chief Financial Officer
J962 shares2026-09-22
Crotty Dylan BramGroup President
Sell441 shares2026-08-21
STRYKER RONDA E-
Sell805 shares2026-08-19
STRYKER RONDA E-
Sell3,852 shares2026-08-19
79/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
64.0%
Net Margin
12.9%
Revenue CAGR
8.3%
Current Ratio
1.89x
Debt / Equity
0.71x
Return on Equity
14.5%
Earnings Summary
Stryker Corporation is a medical technology firm that delivers innovative solutions across its MedSurg, Neurotechnology, and Orthopaedics segments, supplying surgical equipment, neurotechnology devices, and joint replacement implants to hospitals worldwide. Operating in the healthcare sector, Stryker’s global distribution network spans 75 countries through direct sales and third‑party channels. In Q1 2026 and Q2 2026, the company posted EPS of $2.60 and $3.69, both below analyst estimates of $2.98 and $3.49, while revenue declined to $6.02 billion and $6.589 billion from estimates of $6.329 billion and $6.646 billion, indicating a slight revenue contraction and earnings miss. Compared to Q3 2025 and Q4 2025, EPS fell from $3.19 to $2.60 and $3.69, and revenue decreased from $6.057 billion to $6.02 billion and $6.589 billion, reflecting a modest slowdown. Historically, Stryker has shown strong revenue growth, with a 9.4% increase in Q4 2025, but EPS has been volatile, with recent misses in Q1 and Q2 2026. Recent news highlights a leadership transition announced on Oct 9, with Kevin Lobo moving to Executive Chair and Spencer Stiles becoming CEO effective Jan 1 2027, and analyst coverage shifts, including Barclays raising the price target to $375 and Truist lowering it to $310, underscoring market sensitivity to executive changes.

EPS

EstBeatMiss
$2.32$2.93$3.54$4.14$4.75Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.56 - -
Q2'26$3.49$3.69+5.8%
Q1'26$2.98$2.60-12.9%
Q4'25$4.44$4.47+0.7%
Q3'25$3.13$3.19+1.9%
Q2'25$3.07$3.13+1.9%

Revenue

EstBeatMiss
$5.8B$6.2B$6.6B$7.0B$7.4BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$6.7B - -
Q2'26$6.6B$6.6B-0.9%
Q1'26$6.3B$6.0B-4.9%
Q4'25$7.2B$7.2B-0.3%
Q3'25 - $6.1B -
Q2'25 - $6.0B -

Market Data

SYK Stock Snapshot

BEARISH16/100
$280.13−$2.42 (0.9%)
Market cap
108.48B
P/E ratio
29.1
Day range
$278.57 – $285.66
News sentiment
64/100 · Bullish
Analyst target
$362.62 (+29.4%)
Consensus
Buy · 36 analysts
52-week range+4.9% off low · -28.6% from high
$267.00$392.55
Price $280.13 DailyIQ Est. $379.24

The trend on SYK is bearish, and its momentum ranks in the lower part of DailyIQ's universe. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into SYK?

RICH

At today's price, Stryker Corporation needs to grow free cash flow about 11.3% a year for the next 10 years to justify its valuation at a 7.80% cost of capital. Over its actual history it has compounded free cash flow at 7.3% a year, so the market is asking for 4.0 percentage points above its own delivered rate. On that basis SYK looks priced above what its own growth record supports.

Implied FCF growth
11.3%
Historical FCF CAGR
7.3%
Growth gap
+4.0 pts
Verdict
RICH
Discount rate (WACC)
7.80%
Beta
0.66

Behaviour On Record

What SYK's own history says about today's numbers

Realized volatility (21d)
24.2% 67th pct
Below its peak
-29.7%
vs 200-day average
-13.5%
Up days (1y)
48%

Stryker Corporation is currently running 24.2% annualised volatility over the last 21 sessions. Measured against SYK's own 13 years of daily returns rather than a market-wide average, that is the 67th percentile — a little above its own norm, against a typical reading of 20.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

SYK is trading -29.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -14.2%, and the deepest was -42.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -13.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 4th percentile — a narrower gap than it typically runs. Over the past year SYK closed higher on 48% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, SYK finished the month higher 7 of 14 times, with a median return of +0.2% and an average of +0.9%. Its strongest month historically has been January at +4.2% on average, its weakest September at -1.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: SYK has opened more than 2% away from the prior close in 87 of 3,268 sessions (2.7% of the time), with the largest gaps running +7.0% and -7.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, SYK moved an average of 2.6% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.9% and a largest of -6.0%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against SYK's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of SYK's sector?

Stryker Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, SYK ranks 3rd of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91
Industry rank
#3 of 15

Options Market

What is the options market pricing for SYK?

CallsPuts

For Stryker Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.84), with at-the-money implied volatility around 32.0%. The options market is pricing roughly a ±2.5% move by that expiry — a range of about $272.67–$286.77.

Put/call ratio (2026-10-16)
0.84
ATM implied volatility
32.0%
Total open interest
5,656
Expected move by 2026-10-16
±2.5% ($272.67–$286.77)

Analyst Rating Changes

Are analysts turning bullish or bearish on SYK?

BTIG most recently reiterated its rating on Stryker Corporation to Buy on Oct 12, 2026 with a price target of $316 (from $358). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
BTIG — Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Oct 12, 2026BTIGMaintainedBuy$358 → $316
Oct 7, 2026Truist SecuritiesMaintainedHold$340 → $310
Oct 7, 2026BarclaysInitiatedOverweight$375
Sep 30, 2026StifelMaintainedBuy$360 → $330
Sep 22, 2026TD CowenMaintainedHold$355 → $298
Sep 18, 2026Canaccord GenuityMaintainedBuy$400 → $385
Sep 10, 2026CitigroupMaintainedBuy$399 → $360
Sep 9, 2026Wells FargoMaintainedOverweight$418 → $348
Aug 13, 2026Wolfe ResearchDowngradeOutperform → Peer Perform-
Aug 3, 2026CitizensMaintainedMarket Outperform$440 → $400
Jul 31, 2026RBC CapitalMaintainedOutperform$435 → $420
Jul 31, 2026JP MorganMaintainedOverweight$400 → $350

Peers & ETF holders

SYK peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

64/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Stryker rebounded in the second quarter of 2026 after a cybersecurity disruption in the previous period, restoring operating momentum. The company reported stronger revenue growth driven by new product launches and expanded market reach. Management highlighted continued investment in innovation and a focus on high-margin segments, positioning the firm for sustained upside.
What did this article say?
The article outlines why investors monitor Stryker (SYK), noting the company’s 20% share decline over six months versus the S&P 500’s gain. It highlights Stryker’s broad product portfolio across orthopedics, surgical tools, neurotechnology, and patient care solutions, and emphasizes the company’s organic growth as a key metric. The piece also references a free research report that discusses potential buying opportunities amid the recent pullback.
What did this article say?
Stryker announced a $400 million investment in CMR Surgical, a company specializing in robotic surgery solutions. The deal includes a future buyout option, giving Stryker the right to acquire the entire company at a later date. The investment positions Stryker to expand its presence in the growing robotic surgery market and potentially gain access to innovative technologies. The transaction is expected to enhance Stryker’s product portfolio and strengthen its competitive edge in minimally invasive procedures. The move is viewed as a strategic expansion rather than a short‑term financial maneuver.
What did this article say?
Stryker announced a $400 million investment in CMR Surgical, granting it a stake and an option to acquire the company outright. The deal positions Stryker to expand its robotics portfolio and gain access to CMR’s minimally invasive surgical technologies. The investment signals confidence in CMR’s growth prospects and aligns with Stryker’s strategy to broaden its digital health offerings. The acquisition option provides flexibility for Stryker to evaluate long‑term synergies before committing to full ownership.
What did this article say?
Stryker Corporation announced a leadership transition, appointing Kevin Lobo as executive chairman and Spencer Stiles as chief executive effective January 1. The change follows a 25% decline in the stock price over the past year, yet the company reported a 9.4% revenue increase and a 44.3% rise in earnings for the most recent quarter. Gross and operating margins remained solid at 65.6% and 27.0% respectively, and free cash flow reached $4.7 billion. The board’s decision appears aimed at restoring investor confidence while maintaining operational momentum.
What did this article say?
Leerink Partners reduced its price target for Stryker (SYK) from $403 to $353, reflecting a more cautious outlook. The firm maintains an overweight rating but notes that the new target aligns with a lower earnings forecast. The adjustment signals a modest negative shift in analyst sentiment toward the company’s near‑term performance.
What did this article say?
Stryker reported a dividend rating of 7 out of 10, reflecting strong profitability and a low payout ratio. The company’s earnings growth remains steady, supporting a sustainable dividend policy. The rating signals a balanced income opportunity for investors seeking yield with relative safety.
What did this article say?
Stryker’s stock fell 26% over the past year, prompting investors to reassess the company’s valuation against its projected cash flows. Analysts highlighted the planned transition from CEO Kevin Lobo to Spencer Stiles in early 2027, noting potential impacts on capital allocation and earnings consistency. The discussion centered on whether the current share price of $275.40 reflects the discounted cash flow value of the firm’s medical technology portfolio.
What did this article say?
Stryker (SYK) disclosed a CEO succession plan, moving Kevin Lobo to Executive Chair and naming Spencer Stiles as CEO starting January 2027. The news triggered a sell‑off, with the stock dropping 8.2% in the past month and 14.9% over three months. Investors are reassessing leadership risk, though the company’s five‑year return remains positive.

Technical Analysis

Real-time indicators across multiple timeframes

16
BEARISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $43.77B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy33,907,2918.86%$11.92B2026-01-29
BlackRock, Inc.▼ Sell27,414,7427.16%$8.63B2026-08-07
JPMorgan Chase & Co▲ Buy17,260,9434.51%$5.71B2026-08-12
Wellington Management Group LLP▲ Buy8,167,1852.13%$2.57B2026-08-14
Geode Capital Management, LLC▲ Buy7,819,8022.04%$2.45B2026-08-12
Morgan Stanley▼ Sell5,960,7321.56%$1.88B2026-08-13
AllianceBernstein L.P.▼ Sell4,927,0211.29%$1.62B2026-08-14
Norges Bank▼ Sell4,892,6151.28%$1.54B2026-08-12
Bank of America Corp▲ Buy4,460,3111.17%$1.40B2026-08-14
Northern Trust Corp▲ Buy3,326,5490.87%$1.05B2026-08-13
Goldman Sachs Group Inc▲ Buy2,783,7820.73%$876.45M2026-08-14
Wells Fargo & Company▲ Buy2,407,6800.63%$758.03M2026-08-14
Janus Henderson Group plc▼ Sell1,958,9160.51%$643.68M2026-05-18
Invesco Ltd.▲ Buy1,855,1620.48%$584.08M2026-08-14
FMR LLC (Fidelity)▼ Sell1,702,3730.44%$535.98M2026-08-13
Capital Research Global Investors▼ Sell1,617,1760.42%$509.15M2026-08-12
Neuberger Berman Group LLC▲ Buy672,9640.18%$211.88M2026-08-13
Citigroup Inc▲ Buy623,7250.16%$196.37M2026-08-03
AQR Capital Management LLC▼ Sell476,0950.12%$149.76M2026-08-14
Point72 Asset Management, L.P.▲ Buy430,0940.11%$135.41M2026-08-14
Fisher Asset Management, LLC▼ Sell395,7740.10%$124.61M2026-08-04
Adage Capital Partners GP, L.L.C.▲ Buy307,4990.08%$96.81M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell270,5540.07%$85.18M2026-08-14
Prudential Financial Inc▼ Sell165,5780.04%$52.13M2026-08-12
Citadel Advisors LLC▼ Sell152,4640.04%$48.00M2026-09-02
Q2 2026 flow:3.80M sh bought ($1.22B)7.49M sh sold ($2.37B)net -3.69M sh (−$1.15B)
Congressional Trading Activity
25 disclosed trades · ~$554.5K est. traded value · 7 buys, 18 sells
MemberChamberStateTypeAmountTradedFiled
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2026-07-222026-08-18
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2026-06-022026-07-15
Alan ArmstrongSenateOK▼ Sell$15K - $50K2026-03-272026-07-21
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2026-01-232026-02-19
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-102026-01-12
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2025-11-202025-12-19
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-10-172025-11-18
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-10-162026-01-13
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2025-09-122025-10-14
Thomas H. KeanHouseNJ07▼ Sell$1K - $15K2025-08-252025-09-18
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2025-07-312025-08-20
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2025-06-262025-07-16
Jefferson ShreveHouseIN06▼ Sell$50K - $100K2025-05-122025-06-22
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-04-172025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-04-072025-05-09
Jefferson ShreveHouseIN06▼ Sell$50K - $100K2025-03-132025-04-11
Thomas H. KeanHouseNJ07▼ Sell$15K - $50K2025-02-262025-03-14
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-01-152025-02-10
Julia LetlowHouseLA05▲ Buy$1K - $15K2024-10-232026-01-13
Dan SullivanSenateAK▼ Sell$1K - $15K2022-11-302023-07-26
John F. ReedSenateRI▼ Sell$15K - $50K2019-02-282019-03-18
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-042019-03-01
John F. ReedSenateRI▼ Sell$1K - $15K2018-03-092018-03-12